For instance, USP22 stabilizes Foxp3 and CD73, enhancing iTreg expression and affecting extracellular adenosine, respectively, thus suppressing tumor immunity.[57, 58, 59] Concurrently, in prostate cancer, the absence of USP22 upregulates the infiltration of myeloid cells and promotes the infiltration of T‐cells and NK cells, improving the response to immune therapy and inhibiting the metastasis of pancreatic cancer cells in a T‐cell‐dependent manner.[60] So far, among all the identified DUBs toward PD‐L1, how the cells choose the given DUB still needs to be determined. This evidence concerns the gene USP22 and prostate cancer.